Overview
Scinus Group, a Utrecht-based startup, has secured a €3 million strategic investment led by Myosotis Investments to accelerate the global rollout of its Osilaris cell expansion platform. This funding addresses the critical challenge of scalable cell therapy manufacturing, enhancing production consistency and reducing contamination risks. The platform is already deployed at leading academic and contract development organizations across Europe. With this investment, Scinus aims to strengthen its governance and operational capabilities while executing its commercial rollout strategy.
Products
Loading...
Recent Deals
Investors: Myosotis Investments
Scinus Group, a Utrecht-based startup, has secured a €3 million strategic investment led by Myosotis Investments to accelerate the global rollout of its Osilaris cell expansion platform. This funding addresses the critical challenge of scalable cell therapy manufacturing, enhancing production consistency and reducing contamination risks. The platform is already deployed at leading academic and contract development organizations across Europe. With this investment, Scinus aims to strengthen its governance and operational capabilities while executing its commercial rollout strategy.